Talon Private Wealth LLC Acquires Shares of 31,676 Elanco Animal Health Incorporated $ELAN

Talon Private Wealth LLC bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 31,676 shares of the company’s stock, valued at approximately $780,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. NewEdge Advisors LLC lifted its stake in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Elanco Animal Health in the second quarter worth about $35,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health during the 2nd quarter worth about $38,000. Root Financial Partners LLC raised its holdings in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after purchasing an additional 592 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health during the 4th quarter valued at about $41,000. Institutional investors own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ELAN shares. TD Cowen lifted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, June 18th. UBS Group increased their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, KeyCorp upped their target price on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.09.

Insider Activity

In other news, Director Paul Herendeen purchased 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $23.68 per share, with a total value of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares in the company, valued at $2,644,748.16. This trade represents a 9.83% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael J. Harrington purchased 5,000 shares of Elanco Animal Health stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average cost of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares of the company’s stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have acquired 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Price Performance

Shares of ELAN opened at $23.19 on Friday. The stock has a market cap of $11.59 billion, a P/E ratio of -56.57, a price-to-earnings-growth ratio of 1.71 and a beta of 1.68. Elanco Animal Health Incorporated has a 1 year low of $18.22 and a 1 year high of $27.98. The stock’s 50-day moving average price is $24.54 and its two-hundred day moving average price is $23.93. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, equities analysts predict that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio is designed to help prevent and treat disease, control parasites, improve animal well-being and support productivity in livestock and aquaculture.

The company’s products include vaccines, parasiticides, antibiotics, animal health pharmaceuticals and nutritional supplements. Its companion animal portfolio serves dogs and cats, while its livestock business provides products for cattle, poultry, swine and aquaculture operations.